CLINIICAL TRIALS NOW ENROLLING:
Aminex
Adult Trial
Phase 1b/2 Trial of AMXT 1501 and DFMO in Combination With Standard Therapies in Patients with Advanced Solid Tumors Including Breast Cancer and Metastatic Melanoma
For more information and list of currently enrolling trial sites, please visit:
Clinicaltrials.gov ID: NCT07287917
This multicenter, open-label trial will evaluate the safety, tolerability and preliminary efficacy of oral AMXT 1501 in combination with oral DFMO in addition to standard of care therapy in metastatic melanoma and in pre- and post-menopausal women with ER+ HER2- breast cancer who have progressed on prior therapies. The study will evaluate safety in dose escalation and efficacy in dose expansion cohorts.
Beat Childhood Cancer Consortium/Penn State University
Pediatric Trial
Phase 1 / 2 Clinical Trial of DFMO and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas (relapsed/refractory neuroblastoma, embryonal tumor with multilayer rosettes, atypical teratoid rhabdoid tumor, ewing sarcoma, osteosarcoma or newly diagnosed diffuse intrinsic pontine glioma)
For more information and list of currently enrolling trial sites, please visit:
Clinicaltrials.gov ID: NCT06465199
Aminex is partnering with The Beat Childhood Cancer Consortium at Penn State College of Medicine on a randomized Phase 1/2 clinical trial of AMXT 1501 plus DFMO in pediatric patients with neuroblastoma, diffuse intrinsic pontine glioma, atypical teratoid rhabdoid tumor, embryonal tumor with multilayer rosettes, ewing sarcoma, and osteosarcoma. (NCT06465199) Aminex also recently announced the receipt of Orphan Drug Designation from the FDA for AMXT 1501 plus DFMO for the treatment of patients with neuroblastoma.
